Skip to main content
SpringerLink
Log in

Minimizing Morbidity from Surgery for Non-seminoma Testicular Cancer

  • Conference paper
Germ Cell Tumours V

Abstract

Most patients with testis cancer are now cured. Efforts to improve treatment are therefore primarily directed to reducing morbidity while maintaining the excellent survival rate. The urological surgical aspects of treatment include the management of the primary tumour as well as retroperitoneal metastases. The concept of scrotal violation, the role for partial orchiectomy and even for percutaneous needle biopsy will be reviewed. The indications for and the necessary extent of retroperitoneal lymphadenectomy (RPL) with nerve sparing as definitive treatment for metastatic disease to the regional nodes have been defined and in general reduced. There is an emerging role for laparoscopic lymphadenectomy for staging and probably therapy. The post chemotherapy residual mass remains a surgical problem. Most patients with detectable disease should undergo surgery. These issues will be addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Dean AL. The treatment of teratoid tumours of the testes with radium and the x-ray.J Urol 1925;13:149.

    Google Scholar 

  2. Capelouto CC, Clark PE, Ransil BJ, Loughlin KR. A review of scrotal violation in testicular cancer: is adjuvant local therapy necessary? J Urol 1995;153:981–985.

    Article  PubMed  CAS  Google Scholar 

  3. Kennedy CL, Hendry WF, Peckham M J. The significance of scrotal interference in stage 1 testicular cancer managed by orchiectomy and surveillance. Brit J Urol 1986;58:705.

    Article  PubMed  CAS  Google Scholar 

  4. Aki FT, Bilen CY, Tekin MI, Ozen H. Is scrotal violation per se a risk factor for local relapse and metastases in stage 1 nonseminomatous testicular cancer? Urology 2000;56:459–462.

    Article  PubMed  CAS  Google Scholar 

  5. Markland C, Kedia K, Fraley EE. Inadequate orchiectomy in patients with testicular tumours. JAMA 1984;224:1025.

    Article  Google Scholar 

  6. Verma K, Ram T, Kapila K. Value of fine needle aspiration cytology in the diagnosis of testicular neoplasms. Acta Cytologica 1989;33(5):631–634.

    PubMed  CAS  Google Scholar 

  7. Linsk JA, Franzen S. Clinical Aspiration Cytology 1983.

    Google Scholar 

  8. Zajicek J. Monographs in Clinical Cytology 1979.

    Google Scholar 

  9. Heidenreich A, Bonfig R, Derschum W, von Vietsch H, Wilbert DM. A conservative approach to bilateral testicular germ cell tumors. J Urol 1995;153:10–13.

    Article  PubMed  CAS  Google Scholar 

  10. Weissbach L. Organ preserving surgery of malignant germ cell tumors. J Urol 1995;153:90–93.

    Article  PubMed  CAS  Google Scholar 

  11. van der Schyff S, Heidenreich A, Weibbach L, Hohlt W. Organ preserving surgery in testicular cancer.J Urol 2000;163(supp):145.

    Google Scholar 

  12. Bokemeyer C, Schmoll H, Schoffski P, al e. Bilateral testicular tumours: Prevalence and clinical implications. Eur J Cancer 1993;6:874.

    Article  Google Scholar 

  13. Richie JP. Simultaneous bilateral tumors with unorthodox management. World J Urol 1984;2:74.

    Google Scholar 

  14. Fossa SD, Opjordsmoen S, Huang E. Androgen replacement and quality of life in patients treated for bilateral testicular cancer. Eur J Cancer 1999;35:1220–1225.

    Article  PubMed  CAS  Google Scholar 

  15. Giwercman A, von der Maase H, Berthelsen JG, Rorth M, Bertelsen A, Skakkebaek NE. Localized irradiation of testes with carcinoma in situ: effects on Leidig cell function and eradication of malignant germ cells in 20 patients. J Clin Endocrinol Metab 1991;73:596.

    Article  PubMed  CAS  Google Scholar 

  16. Fordham MVP, Mason MD, Blackmore C, Hendry WF, Horwich A. Management of the contralateral testis in patients with testicular germ cell cancer. J Urol 1990;65:290–293.

    Article  CAS  Google Scholar 

  17. Heidenreich A, Hofmann R. Quality-of-life issues in the treatment of testicular cancer. World J Urol 1999;17:230–238.

    Article  PubMed  CAS  Google Scholar 

  18. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Retroperitoneal lymphadenectomy for clinical stage A testis cancer (1965–1989): modifications of technique and impact on ejaculation. J Urol 1993;149:237–247.

    PubMed  CAS  Google Scholar 

  19. Pizzocaro G. Retroperitoneal lymphadenectomy in clinical stage I nonseminomatous germinal testis cancer. Eur J Surg Oncology 1986;12: 25–28.

    CAS  Google Scholar 

  20. Aass N, Fossa SD, Ous S, et al. Is routine primary retroperitoneal lymph node dissection still justified in patients with low stage non-seminomatous testicular cancer? Brit J Urol 1990;65: 385–90.

    Article  PubMed  CAS  Google Scholar 

  21. Klepp O, Olsson AM, Henrikson H, et al. Prognostic factors in clinical stage I nonseminomatous germ cell tumors of the testis: multivariate analysis of a prospective multicenter study. J Clin Oncol 1990;8:509–518.

    PubMed  CAS  Google Scholar 

  22. Richie JP. Clinical stage I testicular cancer: the role of modified retroperitoneal lymphadenctomy. J Urol 1990; 144:1160.

    PubMed  CAS  Google Scholar 

  23. McLeod DG, Weiss RB, Stablein DM, et al. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup study. J Urol 1991;145:1178–1183.

    PubMed  CAS  Google Scholar 

  24. Donohue JP, Thornhill JA, Foster RS, Bihrle R, Rowland RG, Einhorn LH. The role of retroperitoneal lymphadenectomy in clinical stage B testis cancer: the Indiana University experience (1965 to 1989). J Urol 1995;153:85–9.

    Article  PubMed  CAS  Google Scholar 

  25. Jewett MA, Incze P. Retroperitoneal lymphadenectomy: the traditional treatment option. Semin Urol Oncol 1996;14:24–9.

    PubMed  CAS  Google Scholar 

  26. Horwich A. Primary chemotherapy: how does it compare with surgery? Semin Urol Oncol 1996;14:34–5.

    PubMed  CAS  Google Scholar 

  27. Foster RS, Donohue JP. Retroperitoneal lymph node dissection for the management of clinical stage I nonseminoma. J Urol 2000;163(6):1788–92.

    Article  PubMed  CAS  Google Scholar 

  28. Ray B, Hajdu SI, Whitmore WFJ. Distribution of lymph node metastases in testicular germinal tumors. Cancer 1974;33:340–348.

    Article  PubMed  CAS  Google Scholar 

  29. Donohue JP, Maynard B, Zachary M. The distribution of nodal metastases in the retroperitoneum from nonseminomatous testis cancer. J Urol 1982;128:315–320.

    PubMed  CAS  Google Scholar 

  30. Weissbach L, Boedefeld EA.. Localization of solitary and multiple metastases in stage II nonseminomatous testis tumor as basis for a modified staging lymph node dissection in stage I. J Urol 1987;138:77–82.

    PubMed  CAS  Google Scholar 

  31. Jewett MA, Kong YS, Goldberg SD, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988;139:1220–4.

    PubMed  CAS  Google Scholar 

  32. Donohue JP, Foster RS, Rowland RG, Bihrle R, Jones J, Geier G. Nerve-sparing retroperitoneal lymphadenectomy with preservation of ejaculation. J Urol 1990;144:287–91; discussion 291–2.

    PubMed  CAS  Google Scholar 

  33. Fossa SD, Klepp O, Ous S, et al. Unilateral retroperitoneal lymph node dissection in patients with nonseminomatous testicular tumor in clinical stage I. Eur Urol 1984;10:17–23.

    PubMed  CAS  Google Scholar 

  34. Pizzocaro G, Salvioni R, Zanoni F. Unilateral lymphadenectomy in intraoperative stage I nonseminomatous germinal testis cancer. J Urol 1985;134:485–9.

    PubMed  CAS  Google Scholar 

  35. Doerr A, Skinner EC, Skinner DG. Preservation of ejaculation through a modified retroperitoneal lymph node dissection in low stage testis cancer. J Urol 1993;149:1472–1474.

    PubMed  CAS  Google Scholar 

  36. Donohue JP. Nerve-sparing retroperitoneal lymphadenectomy for testis cancer. Evolution of surgical templates for low-stage disease. Eur Urol 1993;23:44–6.

    PubMed  Google Scholar 

  37. Jewett MA, Kong YS, Goldberg SD, et al. Retroperitoneal lymphadenectomy for testis tumor with nerve sparing for ejaculation. J Urol 1988;139:1220–4.

    PubMed  CAS  Google Scholar 

  38. Jewett MA. Nerve-sparing technique for retroperitoneal lymphadenectomy in testis cancer. Urol Clin North Am 1990;17:449–56.

    PubMed  CAS  Google Scholar 

  39. Sheinfeld J, Bajorin D. Management of the postchemotherapy residual mass. Urol Clin North Am 1993;20:133–43.

    PubMed  CAS  Google Scholar 

  40. Einhorn LH, Williams SD, Mandelbaum I, Donohue JP. Surgical resection in disseminated testicular cancer following chemotherapeutic cytoreduction. Cancer 1981;48:904–8.

    Article  PubMed  CAS  Google Scholar 

  41. Fox EP, Weathers TD, Williams SD, et al. Outcome analysis for patients with persistent nonteratomatous germ cell tumor in postchemotherapy retroperitoneal lymph node dissections. J Clin Oncol 1993;11:1294–9.

    PubMed  CAS  Google Scholar 

  42. Donohue JP, Foster RS. Retroperitoneal lymphadenectomy in staging and treatment. The development of nerve-sparing techniques. Urol Clin North Am 1998;25:461–8.

    Article  PubMed  CAS  Google Scholar 

  43. Donohue JP, Rowland RG. The role of surgery in advanced testicular cancer. Cancer 1984;54:2716–21.

    Article  PubMed  CAS  Google Scholar 

  44. Wood DP, Jr., Herr HW, Heller G, et al. Distribution of retroperitoneal metastases after chemotherapy in patients with nonseminomatous germ cell tumors. J Urol 1992;148:1812–5; discussion 1815–6.

    PubMed  Google Scholar 

  45. Wahle GR, Foster RS, Bihrle R, Rowland RG, Bennett RM. Nerve sparing retroperitoneal lymphadenectomy after primary chemotherapy for metastatic testicular carcinoma. J Urol 1994;152:428–430.

    PubMed  CAS  Google Scholar 

  46. Coogan CL, Hejase MJ, Wahle GR, et al. Nerve sparing post-chemotherapy retroperitoneal lymph node dissection for advanced testicular cancer. J Urol 1996;156:1656–8.

    Article  PubMed  CAS  Google Scholar 

  47. Aprikian AG, Herr HW, Bajorin DF, Bosl GJ. Resection of postchemotherapy residual masses and limited retroperitoneal lymphadenectomy in patients with metastatic testicular nonseminomatous germ cell tumors. Cancer 1994;74:1329–34.

    Article  PubMed  CAS  Google Scholar 

  48. Herr HW. Does necrosis on frozen-section analysis of a mass after chemotherapy justify a limited retroperitoneal resection in patients with advanced testis cancer? Br J Urol 1997;80(4):653–7.

    Article  PubMed  CAS  Google Scholar 

  49. Ozen H, Ekici S, Sozen S, Ergen A, Tekgul S, Kendi S. Resection of residual masses alone: an alternative in surgical therapy of metastatic testicular germ cell tumors after chemotherapy. Urology 2001;57:323–7.

    Article  PubMed  CAS  Google Scholar 

  50. Rabbani F, Gleave ME, Coppin CM, Murray N, Sullivan LD. Teratoma in primary testis tumor reduces complete response rates in the retroperitoneum after primary chemotherapy. The case for primary retroperitoneal lymph node dissection of stage IIb germ cell tumors with teratomatous elements. Cancer 1996;78:480–6.

    Article  PubMed  CAS  Google Scholar 

  51. Jewett MAS, Wesley-James T. Early and late complcations of retroperitoneal lymphadenectomy. Can J Surg 1991;34:368–373.

    PubMed  CAS  Google Scholar 

  52. Baniel J, Foster RS, Rowland RG, Bihrle R, Donohue JP. Complications of post-chemotherapy retroperitoneal lymph node dissection. J Urol 1995;153:976–80.

    Article  PubMed  CAS  Google Scholar 

  53. Baniel J, Sella A. Complications of retroperitoneal lymph node dissection in testicular cancer: primary and post-chemotherapy. Semin Surg Oncol 1999;17:263–7.

    Article  PubMed  CAS  Google Scholar 

  54. Rukstalis DB, Chodak GW. Laparoscopic retroperitoneal lymph node dissection in a patient with stage 1 testicular carcinoma. J Urol 1992;148(6):1907–9.

    PubMed  CAS  Google Scholar 

  55. Janetschek G, Hobisch A, Holtl L, Bartsch G. Retroperitoneal lymphadenectomy for clinical stage I nonseminomatous testicular tumor: laparoscopy versus open surgery and impact of learning curve. J Urol 1996;156:89–93.

    Article  PubMed  CAS  Google Scholar 

  56. Janetschek G, Hobisch A, Hittmair A, Holtl L, Peschel R, Bartsch G. Laparoscopic retroperitoneal lymphadenectomy after chemotherapy for stage IIB nonseminomatous testicular carcinoma. J Urol 1999;161:477–81.

    Article  PubMed  CAS  Google Scholar 

  57. Janetschek G, Hobisch A, Peschel R, Bartsch G. Laparoscopic retroperitoneal lymph node dissection. Urology 2000;55:136–40.

    Article  PubMed  CAS  Google Scholar 

  58. Janetschek G. Laparoscopic retroperitoneal lymph node dissection. Urol Clin North Am 2001;28:107–14.

    Article  PubMed  CAS  Google Scholar 

  59. Rorth M, Jacobsen GK, von der Maase H, et al. Surveillance alone versus radiotherapy after orchiectomy for clinical stage I nonseminomatous testicular cancer. Danish Testicular Cancer Study Group. J Clin Oncol 1991;9:1543–8.

    PubMed  CAS  Google Scholar 

  60. Read G, Stenning SP, Cullen MH, et al. Medical Research Council prospective study of surveillance for stage I testicular teratoma. J Clin Oncol 1992;10:1762–68.

    PubMed  CAS  Google Scholar 

  61. Swanson D. The case for observation of patients with clinical stage I noseminomatous germ cell testicular tumors. Semin Urol 1993;11:92–98.

    PubMed  CAS  Google Scholar 

  62. Ondrus D, Hornak M. Orchiectomy alone for clinical stage I nonseminomatous germ cell tumors of the testis (NSGCTT): a minimum follow-up period of 5 years. Tumori 1994;80:362–4.

    PubMed  CAS  Google Scholar 

  63. Nicolai N, Pizzocaro G. A surveillance study of clinical stage I nonseminomatous germ cell tumors of the testis: 10-year followup. J Urol 1995;154:1045–9.

    Article  PubMed  CAS  Google Scholar 

  64. Gels ME, Hoekstra HJ, Sleijfer DT, et al. Detection of recurrence in patients with clinical stage I nonseminomatous testicular germ cell tumors and consequences for further follow-up: a single-center 10-year experience. J Clin Oncol 1995;13:1188–94.

    PubMed  CAS  Google Scholar 

  65. Sogani PC, Perrotti M, Herr HW, Fair WR, Thaler HT, Bosl G. Clinical stage I testis cancer: long-term outcome of patients on surveillance. J Urol 1998;159:855–8.

    Article  PubMed  CAS  Google Scholar 

  66. Hao D, Seidel J, Brant R, et al. Compliance of clinical stage I nonseminomatous germ cell tumor patients with surveillance. J Urol 1998;160:768–71.

    Article  PubMed  CAS  Google Scholar 

  67. Colls BM, Harvey VJ, Skelton L, et al. Late results of surveillance of clinical stage I nonseminoma germ cell testicular tumours: 17 years’ experience in a national study in New Zealand. BJU Int 1999;83:76–82.

    Article  PubMed  CAS  Google Scholar 

  68. Sharir S, Jewett MAS, Sturgeon J, et al. Progression detection of stage I nonseminomatous testis cancer on surveillance: Implications for the follow up protocol. J Urol 1999;161:472–476.

    Article  PubMed  CAS  Google Scholar 

  69. Javadpour N, Canning DA, O’Connell KJ, Young JD. Predictors of recurrent clinical stage I nonseminomatous testicular cancer. A prospective clinicopathologic study. Urology 1986;27:508–11.

    Article  PubMed  CAS  Google Scholar 

  70. Richie JP. Clinical stage 1 testicular cancer: the role of modified retroperitoneal lymphadenectomy. J Urol 1990;144:1160–3.

    PubMed  CAS  Google Scholar 

  71. McLeod DG, Weiss RB, Stablein DM, et al. Staging relationships and outcome in early stage testicular cancer: a report from the Testicular Cancer Intergroup Study. J Urol 1991;145:1178–83.

    PubMed  CAS  Google Scholar 

  72. Donohue JP, Thornhill JA, Foster RS, Rowland RG, Bihrle R. Primary retroperitoneal lymph node dissection in clinical stage A non-seminomatous germ cell testis cancer. Review of the Indiana University experience 1965–1989. Br J Urol 1993;71:326–35.

    Article  PubMed  CAS  Google Scholar 

  73. Gerber GS, Bissada NK, Hulbert JC, et al. Laparoscopic retroperitoneal lymphadenectomy: multi-institutional analysis. J Urol 1994;152:1188–91.

    PubMed  CAS  Google Scholar 

  74. Klotz L. Laparoscopic retroperitoneal lymphadenectomy for high-risk stage 1 nonseminomatous germ cell tumor: report of four cases. Urology 1994;43:752–6.

    Article  PubMed  CAS  Google Scholar 

  75. Rassweiler JJ, Frede T, Lenz E, Seemann O, Aiken P. Long-term experience with laparoscopic retroperitoneal lymph node dissection in the management of low-stage testis cancer. Eur Urol 2000;37:251–60.

    Article  PubMed  CAS  Google Scholar 

  76. Giusti G, Beltrami P, Tallarigo C, Bianchi G, Mobilio G. Unilateral laparoscopic retroperitoneal lymphadenectomy for clinical stage I nonseminomatous testicular cancer. J Endourol 1998;12:561–6.

    Article  PubMed  CAS  Google Scholar 

  77. Zhuo Y, Klaen R, Sauter TW, Miller K. Laparoscopic retroperitoneal lymph node dissection in clinical stage I nonseminomatous germ cell tumor: a minimal invasive alternative. Chin Med J (Engl) 1998;111:537–41.

    CAS  Google Scholar 

  78. Nelson JB, Chen RN, Bishoff JT, et al. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology 1999;54:1064–7.

    Article  PubMed  CAS  Google Scholar 

  79. Janetschek G, Hobisch A, Peschel R, Hittmair A, Bartsch G. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous testicular carcinoma: long-term outcome. J Urol 2000;163:1793–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Princess Margaret, Toronto General Hospital and the University of Toronto, Canada

    M. A. S. Jewett, B. Shekarriz & A. Grabowski

Authors
  1. M. A. S. Jewett
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Shekarriz
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Grabowski
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. ICRF Cancer Medicine Research Unit, St James’s University Hospital, Leeds, UK

    Patricia Harnden MD, PhD, FRCPath, MBA

  2. Huddersfield Royal Infirmary, Huddersfield, UK

    Johnathan K. Joffe MB BS, MD, FRCP

  3. Yorkshire Centre for Cancer Treatments, Cookridge Hospital, Leeds, UK

    William G. Jones MB CHB, FRCR, DMRT

Rights and permissions

Reprints and permissions

Copyright information

© 2002 Springer-Verlag London Limited

About this paper

Cite this paper

Jewett, M.A.S., Shekarriz, B., Grabowski, A. (2002). Minimizing Morbidity from Surgery for Non-seminoma Testicular Cancer. In: Harnden, P., Joffe, J.K., Jones, W.G. (eds) Germ Cell Tumours V. Springer, London. https://doi.org/10.1007/978-1-4471-3281-3_41

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-3281-3_41

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-3283-7

  • Online ISBN: 978-1-4471-3281-3

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation